HC Wainwright Lowers Earnings Estimates for Xeris Biopharma

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Equities research analysts at HC Wainwright lowered their FY2027 EPS estimates for Xeris Biopharma in a report released on Monday, November 11th. HC Wainwright analyst O. Livnat now expects that the company will post earnings of $0.19 per share for the year, down from their prior forecast of $0.27. HC Wainwright has a “Buy” rating and a $6.60 price objective on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.40) per share.

Separately, Piper Sandler cut shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target on the stock. in a report on Monday.

Xeris Biopharma Trading Down 4.0 %

XERS stock opened at $3.15 on Tuesday. Xeris Biopharma has a twelve month low of $1.46 and a twelve month high of $3.64. The firm’s fifty day simple moving average is $2.98 and its two-hundred day simple moving average is $2.52.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in XERS. Vanguard Group Inc. grew its holdings in shares of Xeris Biopharma by 7.3% in the first quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock worth $16,810,000 after purchasing an additional 519,897 shares during the last quarter. Alpine Global Management LLC lifted its stake in Xeris Biopharma by 11.1% in the first quarter. Alpine Global Management LLC now owns 300,000 shares of the company’s stock worth $663,000 after acquiring an additional 30,000 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Xeris Biopharma by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 125,635 shares of the company’s stock worth $278,000 after acquiring an additional 10,632 shares during the period. NEA Management Company LLC purchased a new stake in Xeris Biopharma in the first quarter worth about $926,000. Finally, Bayesian Capital Management LP purchased a new stake in Xeris Biopharma in the first quarter worth about $37,000. 42.75% of the stock is currently owned by institutional investors.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.